

DOCKET NO.: CEPH-3134
Application No.: 10/698,625
Office Action Dated: May 24, 2006

PATENT

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

RECEIVED
CENTRAL FAX CENTER

1-23. (canceled)

AUG 23 2006

24. (currently amended) A method of treating ~~cancer~~ acute myelogenous leukemia in a human, which comprises administering to the human a combination of (i) a therapeutically effective amount of ~~one or more arsenic compounds~~ arsenic trioxide, and (ii) radiation.

25. (canceled)

26. (currently amended) The method of ~~claim 25~~ claim 24, wherein the arsenic trioxide is formulated as an ionic aqueous solution.

27. (currently amended) The method of claim 24, wherein the total daily amount administered of the arsenic ~~compound~~ trioxide is from about 10 g to about 200 mg.

28. (currently amended) The method of claim 24, wherein the total daily amount administered of the arsenic ~~compound~~ trioxide is from about 0.5 mg to about 150 mg.

29. (currently amended) The method of claim 24, wherein the total daily amount administered of the arsenic ~~compound~~ trioxide is from about 0.5 mg to about 70 mg.

30. (currently amended) The method of claim 24, wherein the arsenic ~~compound~~ trioxide is administered parenterally.

31. (currently amended) The method of claim 24, wherein the arsenic ~~compound~~ trioxide is administered intravenously.

32. (currently amended) The method of claim 24, wherein the radiation and the arsenic ~~compound~~ trioxide are administered in combination with an effective amount of at least one further therapeutic agent.

DOCKET NO.: CEPH-3134
Application No.: 10/698,625
Office Action Dated: May 24, 2006

PATENT

33. (previously presented) The method of claim 32, wherein the further therapeutic agent is a chemotherapeutic or radiotherapeutic.

34. (previously presented) The method of claim 32, wherein the further therapeutic agent is selected from the group consisting of etoposide, cisplatin, carboplatin, estramustine phosphate, vinblastine, methotrexate, hydroxyurea, cyclophosphamide, doxorubicin, 5-fluorouracil, taxol, diethylstilbestrol, VM-26(vumon), BCNU, all-trans retinoic acid, procarbazine, cytokines, therapeutic vaccines, and immunomodulators.

35. (currently amended) The method of ~~claim 25~~ claim 24, wherein the dose is varied according to the body weight of the human.

36-42. (canceled)

43. (currently amended) The method of ~~claim 25~~ claim 24, wherein the radiation is administered prior to the arsenic trioxide.

44. (currently amended) The method of ~~claim 25~~ claim 24, wherein the radiation is administered after to the arsenic trioxide.

45. (currently amended) The method of ~~claim 25~~ claim 24, wherein the radiation and the arsenic trioxide are administered concurrently.

46. (canceled)